Product Details
| Product Name:
GW843682X |
CAS No.:
660868-91-7 |
| Purity:
99.92% |
Supply Ability:
10g |
| Release date:
2025/12/03 |
Product Introduction
Bioactivity
| Name | GW843682X |
| Description | GW843682X (GW843682) is a selective and ATP-competitive inhibitor of PLK1 and PLK3 (IC50s = 2.2 nM and 9.1 nM). |
| In vitro | GW843682X (500 nM) in combination with 5 µM VP-16 suppresses 50% of entry into mitosis in U937 cells. GW843682X inhibits the proliferation of U937 cells with an EC50 of 120 nM[1]. GW843682X (0.06-1 μM) has inhibitory activities against the proliferation of acute leukemia cells and potentiates the anti-proliferative activity of vincristine. GW843682X (0.1-1 μM) induces apoptosis of leukemia cells in a dose- and time-dependent manner. GW843682X (0.5-1 μM) dephosphorylates Bcl-xl in leukemia cells[2]. GW843682X is effective in inhibition of growth of tumor cells, with IC50s of 0.41, 0.57, 0.11, 0.38, and 0.70 μM for A549, BT474, HeLa, H460 and HCT116 cell lines. GW843682X dose-dependently inhibits PLK1 phosphorylation of Ser15-p53 (IC50 = 0.14 μM). GW843682X (3 μM) causes strong G2-M arrest in HDF cells and H460 cells after treatment for 24, 48, and 72 h. GW843682X (5 μM) leads to apoptosis in H460 cells instead of HDF cells[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 30 mg/mL (62.83 mM), Sonication is recommended.
|
| Keywords | VEGFR2 | Polo-like Kinase (PLK) | PLK3 | PLK1 | PDGFRβ | PDGFR1β | GW843682X | GW-843682 | GW 843682 | CDK2/CyclinA | CDK2/cyclin A | AuroraKinase | Aurora Kinase | Aurora A |
| Inhibitors Related | 2-Chloropyrazine | Kojic acid | Sorafenib | Pyridoxine | Abemaciclib | glycine | Nintedanib esylate | Ethyl cinnamate | Palbociclib | Sodium Oxamate | Lenvatinib | Pazopanib |
| Related Compound Libraries | Highly Selective Inhibitor Library | Anti-Lung Cancer Compound Library | Reprogramming Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Ovarian Cancer Compound Library | Anti-Breast Cancer Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:1987854-08-9
$1070.00 / 10mg
-
CAS:2728500-80-7
$50.00 / 5mg
-
CAS:515-13-9
$129.00 / 100mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$1.00/1g |
VIP6Y
|
Career Henan Chemical Co
|
2020-01-10 |
United States